XTX Topco Ltd Acquires 8,946 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

XTX Topco Ltd lifted its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 406.6% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 11,146 shares of the biotechnology company’s stock after purchasing an additional 8,946 shares during the period. XTX Topco Ltd’s holdings in Blueprint Medicines were worth $972,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Y Intercept Hong Kong Ltd increased its position in Blueprint Medicines by 27.6% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 2,662 shares of the biotechnology company’s stock valued at $246,000 after acquiring an additional 576 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Blueprint Medicines by 1.4% during the third quarter. Geode Capital Management LLC now owns 1,480,187 shares of the biotechnology company’s stock valued at $136,942,000 after purchasing an additional 20,703 shares during the last quarter. Teachers Retirement System of The State of Kentucky increased its holdings in shares of Blueprint Medicines by 23.7% in the third quarter. Teachers Retirement System of The State of Kentucky now owns 16,520 shares of the biotechnology company’s stock valued at $1,528,000 after purchasing an additional 3,162 shares in the last quarter. Sanctuary Advisors LLC bought a new position in Blueprint Medicines in the 3rd quarter worth approximately $202,000. Finally, Synovus Financial Corp lifted its holdings in Blueprint Medicines by 4.0% during the 3rd quarter. Synovus Financial Corp now owns 24,047 shares of the biotechnology company’s stock worth $2,224,000 after buying an additional 922 shares in the last quarter.

Insider Buying and Selling

In other Blueprint Medicines news, insider Ariel Hurley sold 3,203 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $92.62, for a total transaction of $296,661.86. Following the completion of the transaction, the insider now owns 18,270 shares of the company’s stock, valued at $1,692,167.40. This represents a 14.92 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Jeffrey W. Albers sold 15,161 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $109.53, for a total transaction of $1,660,584.33. Following the transaction, the director now directly owns 152,396 shares of the company’s stock, valued at $16,691,933.88. This represents a 9.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 24,358 shares of company stock valued at $2,583,187. Company insiders own 4.21% of the company’s stock.

Blueprint Medicines Trading Down 1.3 %

NASDAQ:BPMC opened at $81.45 on Wednesday. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. The business’s 50-day simple moving average is $89.79 and its 200-day simple moving average is $93.39. Blueprint Medicines Co. has a fifty-two week low of $73.04 and a fifty-two week high of $121.90. The stock has a market capitalization of $5.21 billion, a PE ratio of -75.42 and a beta of 0.75.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. Sell-side analysts expect that Blueprint Medicines Co. will post -1.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Needham & Company LLC restated a “buy” rating and set a $133.00 target price on shares of Blueprint Medicines in a research report on Tuesday, April 8th. HC Wainwright restated a “buy” rating and set a $135.00 target price on shares of Blueprint Medicines in a research report on Friday, February 14th. Wolfe Research initiated coverage on shares of Blueprint Medicines in a research note on Tuesday, March 18th. They issued an “outperform” rating on the stock. JPMorgan Chase & Co. boosted their price target on shares of Blueprint Medicines from $126.00 to $129.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 4th. Finally, Morgan Stanley started coverage on shares of Blueprint Medicines in a report on Thursday, March 20th. They set an “equal weight” rating and a $100.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $124.95.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.